Report Overview
The Japan Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 18.8%, reaching USD 944.7 million in 2031 from USD 400.0 million in 2026.
Highlights:
- 1Diabetic patients actively using real-time CGM devicesIndividuals are continuously monitoring blood glucose levels for better daily diabetes management.
- 2Hospitals integrating advanced CGM systemsHealthcare facilities are adopting continuous monitors to enhance patient care and outcomes.
- 3Government expanding reimbursement policiesAuthorities are supporting wider CGM access through new insurance coverage initiatives.
- 4Manufacturers launching innovative CGM sensorsCompanies are developing advanced technologies to improve accuracy and user convenience.
- 5Clinics offering CGM solutionsDiagnostic centers are providing continuous glucose monitoring for effective diabetes treatment.
- 6Patients utilizing CGM smartphone applicationsUsers are leveraging real-time apps to make informed decisions about diet and medication.
Japan Continuous Glucose Monitoring Market:
Continuous sugar monitoring (CGM), sometimes referred to as sugar continuous glucose monitoring, automatically monitors blood glucose throughout the day. Making more educated choices about maintaining daily medication use, a healthy diet, and physical activity can be aided with real-time glucose monitoring. A small sensor used in CGM is implanted beneath the skin, often on the arm or abdomen. The sensor picks up interstitial glucose, which is present in the intercellular fluid. The sensor examines the glucose level every few minutes, and wireless data transmission sends the results to a monitor.
Moreover, the closed-loop bionic/artificial pancreas has been given a blueprint because of CGMS-based technologies. Thus, businesses that manufacture glucose monitoring devices concentrate largely on creating novel and cutting-edge CGMS. It has several applications for healthcare settings (hospital ICUs, diagnostic centers, and clinics), for all age groups, and geographical locations. A growing awareness of diabetes preventative care, new product debuts, government efforts, and the CGM device market are the major market drivers for CGM Market.
Diabetes is a complicated, chronic condition that can lead to myocardial infarction, stroke, neuropathy, blindness, and renal damage. For patients to avoid aggravation and the beginning of problems, daily glucose level management is essential. With their recent development, real-time continuous glucose monitoring (CGM) apps have been created for smartphones and other devices connected to CGM systems. These CGM apps are also utilized in Japan. Using CGM applications enhances patients' blood glucose management as compared to conventional retrospective CGM, which is anticipated to aid in slowing the course of type 2 diabetes mellitus (DM) and preventing complications. Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion.
Japan Continuous Glucose Monitoring Market Drivers:
The number of patients with Type-1 and Type-2 diabetes in Japan is expected to surge growth.
Type 1, also known as insulin-requiring diabetes, is brought on by immune system failure, whereas Type 2, sometimes referred to as insulin-dependent diabetes, is caused by adoption of a sedentary lifestyle. Type 2 diabetes is prevalent in Japan due to the senior population. To prevent various diseases, including renal issues, cardiovascular diseases, and other ailments, the blood glucose level is monitored using continuous glucose monitoring. Another explanation is that more people have had their illnesses identified after being referred to a hospital due to the findings of a metabolic syndrome screening.
CGM sensors are the prevailing factor for market growth.
CGM sensors are a prominent market shareholder. Hydrogen peroxide is formed when platinum reacts with glucose oxidase in the CGM sensor. Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion. CGM has been a popular substitute for portable finger-prick glucometers, providing convenience to diabetic patients, which will upsurge the market in Japan.
Japan Continuous Glucose Monitoring Market Developments:
In December 2022, the Dexcom G6 CGM System now has increased payment coverage under the Japanese medical insurance system, according to a Terumo Company announcement. A larger population of patients with diabetes will be able to get reimbursement utilizing the Dexcom G6 CGM System in Japan, thanks to the recently created category of "C150."
In March 2022, the Japanese Ministry of Health, Labour, and Welfare gave the go-ahead for the FreeStyle® Libre system's reimbursement coverage to be expanded to encompass all diabetics who take insulin at least once per day, according to a statement released by Abbott.
Japan Continuous Glucose Monitoring (CGM) Market Scope:
| Report Metric | Details |
|---|---|
| Total Market Size in 2026 | USD 400.0 million |
| Total Market Size in 2031 | USD 944.7 million |
| Forecast Unit | Million |
| Growth Rate | 18.8% |
| Study Period | 2021 to 2031 |
| Historical Data | 2021 to 2024 |
| Base Year | 2025 |
| Forecast Period | 2026 – 2031 |
| Segmentation | Application, End-User Industry |
| Companies |
|
Japan Continuous Glucose Monitoring (CGM) Market Segmentation:
By Application
Diabetes Patients
Critical Patients
By End-User Industry
Hospitals
Diagnostic Centers & Clinics
Home Care
Market Segmentation
By Application
- Diabetes Patients
- Critical Patients
By End-User Industry
- Hospitals
- Diagnostic Centers & Clinics
- Home Care
Table of Contents
1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. JAPAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY APPLICATION
5.1. Introduction
5.2. Diabetes Patients
5.3. Critical Patients
6. JAPAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET, BY END-USER INDUSTRY
6.1. Introduction
6.2. Hospitals
6.3. Diagnostic Centers & Clinics
6.4. Home Care
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. Dexcom, Inc.
8.2. Abbott Laboratories
8.3. Medtronic plc
8.4. Nipro Corporation
8.5. Panasonic Healthcare Co., Ltd.
8.6. Terumo Corporation
8.7. Roche Diabetes Care, Inc.
8.8. Omron Healthcare Co., Ltd.
8.9. Fukuda Denshi Co., Ltd.
8.10. Arkray, Inc.
Navigate
Trusted by the world's leading organizations











